[Loss of p16 gene in bladder cancer and genitourinary carcinoma cell lines].
To determine whether p16, a novel antioncogene, is altered in human bladder cancer and urogenital carcinoma cell lines, we examined a series of 10 primary bladder cancer and 4 urogenital carcinoma cell lines (BIU-87, EJ, GRC and PC-3M) by southern blot. Two cases of 10 primary bladder cancer and EJ, BIU-87 PC-3M had homozygous deletion of p16, and 2 cases of 10 primary bladder cancer had loss of heterozygous. Loss of p16 may provide an additional growth advantage and carcinogenesis.
Guo
D
D
Institute of Urology, Beijing Medical University.
Gu
F
F
Zhou
A
A
D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology; D002295:Carcinoma, Transitional Cell / Q000235:genetics* / Q000473:pathology; D005260:Female; D017353:Gene Deletion; D019942:Genes, p16; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics* / Q000473:pathology; D019656:Loss of Heterozygosity; D008297:Male; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology